spacer
spacer

PDBsum entry 2esl

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Isomerase/immunosuppressant PDB id
2esl

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
(+ 0 more) 181 a.a. *
(+ 0 more) 11 a.a. *
Ligands
SO4 ×6
Metals
_CA ×3
_ZN ×2
Waters ×798
* Residue conservation analysis
PDB id:
2esl
Name: Isomerase/immunosuppressant
Title: Human cyclophilin c in complex with cyclosporin a
Structure: Peptidyl-prolyl cis-trans isomerasE C. Chain: a, b, c, d, e, f. Fragment: residues 24-212. Synonym: ppiasE C,cyclophilin c,rotamasE C. Engineered: yes. Cyclosporin a. Chain: i, j, k, l, m, n. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: ppic, cypc. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008. Synthetic: yes. Tolypocladium inflatum. Organism_taxid: 29910
Biol. unit: Dodecamer (from PQS)
Resolution:
1.90Å     R-factor:   0.180     R-free:   0.225
Authors: J.R.Walker,T.Davis,E.M.Newman,P.J.Finerty Jr.,F.Mackenzie,J.Weigelt, M.Sundstrom,C.Arrowsmith,A.Edwards,A.Bochkarev,S.Dhe-Paganon, Structural Genomics Consortium (Sgc)
Key ref: T.L.Davis et al. (2010). Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. Plos Biol, 8, e1000439. PubMed id: 20676357
Date:
26-Oct-05     Release date:   13-Dec-05    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P45877  (PPIC_HUMAN) -  Peptidyl-prolyl cis-trans isomerase C from Homo sapiens
Seq:
Struc:
212 a.a.
181 a.a.
Protein chains
No UniProt id for this chain
Struc: 11 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: Chains A, B, C, D, E, F: E.C.5.2.1.8  - peptidylprolyl isomerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: [protein]-peptidylproline (omega=180) = [protein]-peptidylproline (omega=0)
Peptidylproline (omega=180)
= peptidylproline (omega=0)
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    Added reference    
 
 
Plos Biol 8:e1000439 (2010)
PubMed id: 20676357  
 
 
Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases.
T.L.Davis, J.R.Walker, V.Campagna-Slater, P.J.Finerty, R.Paramanathan, G.Bernstein, F.MacKenzie, W.Tempel, H.Ouyang, W.H.Lee, E.Z.Eisenmesser, S.Dhe-Paganon.
 
  ABSTRACT  
 
Peptidyl-prolyl isomerases catalyze the conversion between cis and trans isomers of proline. The cyclophilin family of peptidyl-prolyl isomerases is well known for being the target of the immunosuppressive drug cyclosporin, used to combat organ transplant rejection. There is great interest in both the substrate specificity of these enzymes and the design of isoform-selective ligands for them. However, the dearth of available data for individual family members inhibits attempts to design drug specificity; additionally, in order to define physiological functions for the cyclophilins, definitive isoform characterization is required. In the current study, enzymatic activity was assayed for 15 of the 17 human cyclophilin isomerase domains, and binding to the cyclosporin scaffold was tested. In order to rationalize the observed isoform diversity, the high-resolution crystallographic structures of seven cyclophilin domains were determined. These models, combined with seven previously solved cyclophilin isoforms, provide the basis for a family-wide structure:function analysis. Detailed structural analysis of the human cyclophilin isomerase explains why cyclophilin activity against short peptides is correlated with an ability to ligate cyclosporin and why certain isoforms are not competent for either activity. In addition, we find that regions of the isomerase domain outside the proline-binding surface impart isoform specificity for both in vivo substrates and drug design. We hypothesize that there is a well-defined molecular surface corresponding to the substrate-binding S2 position that is a site of diversity in the cyclophilin family. Computational simulations of substrate binding in this region support our observations. Our data indicate that unique isoform determinants exist that may be exploited for development of selective ligands and suggest that the currently available small-molecule and peptide-based ligands for this class of enzyme are insufficient for isoform specificity.
 

 

spacer

spacer